The oncolytic vaccinia virus armed with IL-10 treatment contributed to significantly reduced frequencies of antiviral T cells, whereas the frequency of tumor-specific CD8+ T cells was comparable to oncolytic vaccinia virus monotherapy at days 8 and 24 post-infusion. Here, CD8A is linked to neoplasm.